泰恩康(301263.SZ):獲得奧硝唑注射液藥品註冊證書
格隆匯3月27日丨泰恩康(301263.SZ)公佈,公司全資子公司山東華鉑凱盛生物科技有限公司(簡稱“華鉑凱盛”)於近日收到國家藥品監督管理局簽發的奧硝唑注射液《藥品註冊證書》。
奧硝唑注射液由羅氏製藥開發,1980年瑞士首上市,隨後在歐洲多國獲批上市,用於厭氧菌感染的術前預防和術後治療以及腸道和肝臟嚴重的阿米巴病。硝基咪唑類是預防和治療厭氧菌感染的首選藥物之一,其中奧硝唑是繼甲硝唑、替硝唑之後上市的第三代硝基咪唑類藥物,與同類相比具有療效確切、適用人羣更廣、不良反應更小等優勢,目前已在臨牀廣泛用於普外科、婦產科、兒科等科室,已被《抗菌藥物臨牀應用指導原則(2015年版)》和《膽道外科抗菌藥物規範化應用專家共識(2019版)》等國內權威指南或專家共識推薦。
根據米內網數據顯示,2021年中國公立醫療機構終端奧硝唑注射劑銷售額超過18億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.